GeoVax Labs Inc GOVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.77
- Day Range
- $0.75–0.80
- 52-Week Range
- $0.64–20.00
- Bid/Ask
- $0.77 / $0.85
- Shares Outstanding
- 7.37M
- Market Cap
- $3.93M
- Volume/Avg
- 130,720 / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 19
- Website
- https://www.geovax.com
Valuation
|
Metric
|
GOVX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.22 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GOVX
|
|---|---|
Quick Ratio | 1.16 |
Current Ratio | 1.54 |
Interest Coverage | — |
Quick Ratio
GOVX
Profitability
|
Metric
|
GOVX
|
|---|---|
Return on Assets (Normalized) | −374.55% |
Return on Equity (Normalized) | −706.59% |
Return on Invested Capital (Normalized) | −638.22% |
Return on Assets
GOVX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<yS^NH | LOCK|!k!f> | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|DLMJkrv | LOCK|tW$& | $81B | |||
| argenx SE ADR
ARGX
| LOCK|dd?$md% | LOCK|nS | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|F?CC!!#z | LOCK|>^%N | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&FB^>@ | LOCK|KL% | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|c!>hmL | LOCK|!H^GD | $29B | |||
| Incyte Corp
INCY
| LOCK|SdJ?k>P | LOCK|w! | $24B | |||
| Moderna Inc
MRNA
| LOCK|BC>&ZlY | LOCK|%# | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|m?@R!C | LOCK|DZ? | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|j@k#mP | LOCK|@#F | $17B |
United States